Immune checkpoint inhibitors have recently become a cornerstone for the treatment of
different advanced cancers. These drugs, represented mainly by monoclonal antibodies anti …

Immune checkpoint inhibitors block the checkpoint molecules. Different types of cancer
immune checkpoint inhibitors have been approved recently: CTLA-4 monoclonal antibodies …

Advances in cancer therapy in the past few years include the development of medications
that modulate immune checkpoint proteins. Cytotoxic T-lymphocyte antigen 4 (CTLA4) and …

Immune checkpoint inhibitors (ICIs) are novel anticancer agents, recently introduced with the
aim of boosting the immune response against tumors. ICIs are monoclonal autoantibodies …

Immune checkpoints are small molecules expressed by immune cells that play critical roles
in maintaining immune homeostasis. Targeting the immune checkpoints cytotoxic T …

Immunotherapy with checkpoint inhibitors has transformed the treatment of cancer, but
frequently results in immune-mediated adverse events affecting multiple organs, amongst …

Monoclonal antibodies targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4), programed cell
death 1 (PD-1), or its ligand (PD-L1) have become the mainstay for advanced malignancies …

Context: In recent years, progress has been made in cancer immunotherapy by the
development of drugs acting as modulators of immune checkpoint proteins, such as the …

Clinical trials in the past decade have established the antitumor effects of immune
checkpoint inhibition as a revolutionary treatment for cancer. Namely, blocking antibodies to …

Immune checkpoint inhibitors have proven to be effective for various advanced neoplasia.
Immune‐related adverse events (irAEs) as a result of increased T cell activation are unique …